Category Archives: Other

Novo Partners for AI Drug Discovery… Again; Novo Two FIH Obesity Studies; Zealand Initiates Ph2 Enicepatide + Petrelintide Obesity Study

Three cardiometabolic-related news items have been observed: nference entered into a partnership with Novo for cardiometabolic research (view press release); Novo initiated two FIH obesity studies (view CT.gov record; view CT.gov record); and Zealand initiated the Ph2 ZYNERGY study of petrelintide + enicepatide for obesity (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Novo Launches Novocare 2.0; Tryngolza sHTG EU Approval; MiniMed Flex EU Launch

Three cardiometabolic-related news items have been observed: Novo launched Novocare 2.0 with a new app (view press release); Ionis/Sobi received EC approval of Tryngolza for sHTG in the EU (view Ionis press release; view Sobi press release); and MiniMed launched Flex in the EU (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Novo ObesityWeek 2026 Presentations; MiniMed Fit FDA Clearance; Corxel Ph2 Oral GLP-1RA Results

Three cardiometabolic-related news items have been observed: Novo presented additional Ph3 results of cagrisema at ObesityWeek 2026 (view press release); MiniMed received FDA clearance for MiniMed Fit (view press release); and Corxel shared full Ph2 data of its oral GLP-1RA for obesity (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Arrowhead Q3 ’26 Earnings; Lilly Breaks Ground on US Manufacturing Facility; Tandem Mobi Tubeless FDA Clearance; November CHMP Highlights; AbbVie Skyrizi + Amylin Combo PsO Study; Vivani Topline Ph1 Sema Implant Data

A series of cardiometabolic-related news items has been observed from Arrowhead Pharmaceuticals, Lilly, Tandem Diabetes Care, EMA, AbbVie, and Vivani Medical. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

FDA Cuts CNPV Program; Blackstone Funds Pfizer’s Obesity Efforts; Berobenatide SUI Study; Orforglipron Approved in China; Zealand and Altimmune Q3 ’26 Earnings; Novo Zenagamtide AMBITION Studies; Novo Partners with DJ Khaled

A series of cardiometabolic-related news items has been observed from FDA, Pfizer, Lilly, Zealand Pharma, Altimmune, and Novo. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Merck’s Ph2 Dual Agonist MASH Data; Lilly Shares Ph3 Taltz + Zepbound Data and Initiates Ph2 Brenipatide MDD Study; Ascletis Submits IND for GLP-1RA/SARA FDC in Obesity; Fauna Discovers Drug Target in Partnership with Lilly; Ribo Registers Ph1 EU Study in sHTG; Novo Commits $200M to World Diabetes Foundation

A series of cardiometabolic-related news items has been observed from Merck, Lilly, Ascletis, Fauna Bio, Suzhou Ribo Life Science, and Novo. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Madrigal Whistleblower Lawsuit; Kailera Q3 ’26 Earnings; Roche Ph3 Enicepatide CVOT; Abbott and Novo APAC Partnership; Pfizer Posts Another Ph3 Berobenatide Study; Novo Cagrisema BP Trial; New Lilly Ph1 Asset; AZ to Acquire Rhythm?; Amgen Repatha RWE Data

A series of cardiometabolic-related news items has been observed from Madrigal, Kailera, Roche, Abbott, Pfizer, Novo, Lilly, AstraZeneca, and Amgen. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here